INOVIO gives eight presentations at the 34th International Papillomavirus Conference


PLYMOUTH MEETING, PA., November 15, 2021 / PRNewswire / – INOVIO (NASDAQ: INO), a biotechnology company focused on bringing precisely engineered DNA drugs to the market to protect people from infectious diseases and to treat cancer and HPV-related diseases, announced today that eight company-sponsored lectures will be given this week at the 34th International Papillomavirus Conference (IPVC), which takes place virtually starting today, 15th of November by Friday 19th November.

“The IPVC meeting provides INOVIO with an exciting opportunity to showcase our work in developing treatments for HPV-related diseases and improving our understanding of the epidemiology and standards of care in these disease states,” said Jeffrey Skolnik, MD, SVP, Clinical Development at INOVIO. “These data underscore our ongoing commitment to developing drugs, technologies and solutions to meet the unmet needs of patients across the spectrum of HPV diseases.”

INOVIO will give two oral presentations and a featured e-poster presentation about its VGX-3100 clinical trials. VGX-3100 is in Phase 3 clinical trials to evaluate the immunotherapy candidate for the treatment of high-grade cervical squamous cell intraepithelial lesions (HSIL) and in Phase 2 clinical trials to evaluate the immunotherapy candidate for treatment to investigate anal and vulvar HSIL.

INOVIO will also present a poster of its Phase 1/2 clinical trial protocol for INO-3107 to evaluate the safety, immunogenicity and efficacy of its use for the potential treatment of recurrent respiratory papillomatosis (RRP) in adults.

In collaboration with Optum Life Sciences, another oral presentation will detail the U.S. epidemiological burden from cervical HSIL and a comprehensive assessment of the effectiveness and safety of the cervical HSIL standard of treatment The United States. Additional oral and poster presentations, co-hosted with Optum Life Sciences, will address the US epidemiological burden of anal and vulvar HSIL and RRP.

The following INOVIO sponsored dates will be presented at IPVC 2021:

  • VGX-3100 for the Treatment of HPV16 / 18-Associated Cervical HSIL: Results of a Phase 3 Study (Abstract # 233)
  • Results of VGX-3100 in the Treatment of HPV16 / 18-Associated Vulvar HSIL: Results of the Phase 2 Open-label Efficacy and Safety Study (Abstract # 164)
  • VGX-3100 for the treatment of HPV16 / 18 attributable anal HSIL: results of a phase 2 study (Abstract # 235)
  • Evaluation of INO-3107 – a novel DNA immunotherapy for the treatment of HPV6 / 11-associated recurrent respiratory papillomatosis (Abstract # 247)
  • Cervical HSIL – US Exposure and Comprehensive Treatment Efficacy and Safety Assessment, 2008-2018: The EACH-WOMAN Project (Abstract # 244)
  • Vulvar High-Grade Squamous Intraepithelial Lesion (HSIL): U.S. Epidemiological Burden in the Post-HPV Vaccine Era, 2015-2019 (Abstract # 156)
  • Anal High Grade Squamous Intraepithelial Lesion (HSIL): U.S. Epidemiology Burden in the Era of HPV Vaccine Adoption, 2015-2019 (Abstract # 161)
  • Recurrent Respiratory Papillomatosis (RRP) – Prevalence of All Age Groups in the United States in 2018 (Abstract # 173)

Via INOVIO’s DNA drug platform

INOVIO currently has 15 clinical development programs focused on HPV-related diseases, cancer and infectious diseases, including coronaviruses related to COVID-19 and MERS. “DNA drugs” are made up of optimized DNA plasmids, which are small circles of double-stranded DNA that are synthesized or reorganized by computer sequencing technology and designed to produce a specific immune response in the body.

INOVIO’s vaccine and immunotherapy candidates deliver optimized plasmids intramuscularly or intradermally directly into cells using INOVIO’s proprietary handheld smart device called CELLECTRA®. The CELLECTRA® device uses a short electrical pulse to reversibly open small pores in the cell so that the plasmids can penetrate. Once inside the cell, the DNA plasmids allow the cell to produce the target antigen. The antigen is naturally processed in the cell and triggers the desired T-cell and antibody-mediated immune responses. Administration with the CELLECTRA® device is intended to ensure that the vaccine is efficiently delivered directly into the body’s cells, where it can trigger an immune response. INOVIO’s vaccine candidates do not affect or alter a person’s own DNA in any way. Potential benefits of INOVIO’s vaccine platform include the rapid development and manufacture of DNA vaccine candidates; the stability of the vaccine candidates, which do not need to be frozen during storage and transport; and the immune response and tolerability observed in clinical trials.

With more than 3,900 patients receiving INOVIO vaccine candidates in more than 12,000 uses in a number of clinical trials, INOVIO has a strong track record of rapidly developing vaccine candidates with the potential to meet urgent global health needs.


INOVIO is a biotechnology company committed to rapidly bringing precisely engineered DNA drugs to market to treat and protect people from infectious diseases, cancer and HPV-related diseases. INOVIO is the first to clinically demonstrate that a DNA vaccine candidate can be delivered directly into body cells via a proprietary intelligent device to generate a robust and tolerable immune response. In particular, INOVIO’s lead therapeutic vaccine candidate VGX-3100 met the primary and secondary endpoints in all evaluable subjects in REVEAL 1, the first of two Phase 3 studies in precancerous cervical dysplasia, and demonstrated the ability to treat both high-grade cervical lesions and the underlying high-risk HPV-16/18. INOVIO is also evaluating INO-4800, a DNA vaccine candidate against COVID-19, in a phase 2/3 clinical trial; whose Phase 3 segment has received regulatory approvals to begin in Colombia, Mexico, Brazil, Philippines, India, Thailand and The United States. INOVIO’s partners, Advaccine Biopharmaceuticals and International Vaccine Institute, are also evaluating INO-4800 in ongoing clinical studies in China and South Korea, respectively.

Partners and employees include Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency / Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense / Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter – Helmet BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research and The Wistar Institute. More information is available at


Media: Jeff Richardson, 267-440-4211, [email protected]
Investors: Ben Matone, 484-362-0076, [email protected]

This press release contains certain forward-looking statements regarding our business, including our plans to develop and commercialize DNA drugs, our expectations regarding our research and development programs, including the planned initiation and conduct of preclinical and clinical trials, and their availability and timing the data from these studies and studies, our ability to successfully manufacture and produce large quantities of our product candidates once they receive regulatory approvals, and planned collaborations with third parties. Actual events or results could differ from expectations set forth herein due to a number of factors, including uncertainties associated with preclinical studies, clinical trials, product development programs, and commercialization activities and results, our ability to secure sufficient manufacturing capacity to mass-produce our product candidates , the availability of funding to support ongoing research and studies to prove the safety and effectiveness of electroporation technology as a delivery mechanism or to develop viable DNA drugs, our ability to support our pipeline of DNA medical devices, the ability of our people to conduct development – and achieve commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the appropriateness and Our capitalization, the availability or potential availability of alternative therapies or treatments for the diseases or employees we are targeting, including alternatives that may be more effective or cost-effective than any therapy or treatment that we and our employees wish to develop, problems with product liability, problems with patents and whether they, or licenses to them, provide us with meaningful protection from others using the Covered Technologies, whether such property rights are enforceable or reasonable or infringe or allegedly infringe upon the rights of others or stand against claims of nullity, and whether we can fund or provide other significant resources, that may be necessary to track, protect or defend them, the amount of corporate spending, evaluations of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government health proposals, and other factors detailed in our Annual Report on Form 10-K for the past year December 31, 2020 , our quarterly report on Form 10-Q for the past quarter September 30, 2021 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any candidate product in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical studies will support the regulatory approvals required for a product to be marketed, or that the forward-looking information contained herein will prove to be accurate. Forward-looking statements speak only as of the date of this publication and we assume no obligation to update or revise these statements unless required by law.

SOURCE INOVIO Pharmaceuticals, Inc.

similar links


Comments are closed.